<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Emergent-Biosolutions-Inc-US29089Q1058">Emergent Biosolutions Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/29/3319011/33240/en/Emergent-BioSolutions-Secures-Contract-Modification-Valued-at-Approximately-52-7-Million-for-ACAM2000-Smallpox-and-Mpox-Vaccinia-Vaccine-Live-from-the-U-S-Government.html">Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government</a>
    </div>

      <div class="me-0 me-md-5">
        GAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services to supply ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) vaccine, ancillaries as well a...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Emergent-Biosolutions-Inc-US29089Q1058">Emergent Biosolutions Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/04/3306708/33240/en/Emergent-BioSolutions-Supports-Victoria-s-Voice-Foundation-s-National-Naloxone-Awareness-Day-to-Help-Save-Lives-from-Opioid-Overdose.html">Emergent BioSolutions Supports Victoria&#39;s Voice Foundation&#39;s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose</a>
    </div>

      <div class="me-0 me-md-5">
        Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Emergent-Biosolutions-Inc-US29089Q1058">Emergent Biosolutions Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/28/3303241/33240/en/Emergent-BioSolutions-Receives-64-5-Million-Contract-Modification-for-BAT-Botulism-Antitoxin-Heptavalent-A-B-C-D-E-F-G-Equine-to-Support-U-S-Biodefense-Strategy.html">Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy</a>
    </div>

      <div class="me-0 me-md-5">
        GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS), for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Emergent-Biosolutions-Inc-US29089Q1058">Emergent Biosolutions Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/20/3298371/33240/en/Emergent-BioSolutions-to-Participate-in-Upcoming-Investor-Conferences.html">Emergent BioSolutions to Participate in Upcoming Investor Conferences</a>
    </div>

      <div class="me-0 me-md-5">
        GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company&#39;s senior management team will participate in the following investor conferences:
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Emergent-Biosolutions-Inc-US29089Q1058">Emergent Biosolutions Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/18/3296654/33240/en/Emergent-BioSolutions-Receives-Saudi-Food-and-Drug-Authority-Approval-for-ACAM2000-Smallpox-and-Mpox-Vaccinia-Vaccine-Live.html">Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]</a>
    </div>

      <div class="me-0 me-md-5">
        GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox  (Vaccinia) Vaccine, Live], for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection. This ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Emergent-Biosolutions-Inc-US29089Q1058">Emergent Biosolutions Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">CNBC</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.cnbc.com/2026/05/11/hantavirus-cases-pharma-stocks-surge-moderna-novavax.html">Hantavirus cases spark surge in pharma and biotech stocks — here&#39;s why</a>
    </div>

      <div class="me-0 me-md-5">
        Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Emergent-Biosolutions-Inc-US29089Q1058">Emergent Biosolutions Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/30/3285513/33240/en/Emergent-BioSolutions-Reports-First-Quarter-2026-Financial-Results.html">Emergent BioSolutions Reports First Quarter 2026 Financial Results</a>
    </div>

      <div class="me-0 me-md-5">
        GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2026.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Emergent-Biosolutions-Inc-US29089Q1058">Emergent Biosolutions Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/30/3284760/33240/en/Emergent-BioSolutions-Receives-Approval-from-Singapore-Health-Sciences-Authority-for-Expanded-Indication-of-ACAM2000-Smallpox-and-Mpox-Vaccinia-Vaccine-Live-to-Include-Mpox.html">Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox</a>
    </div>

      <div class="me-0 me-md-5">
        GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Singapore&#39;s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in adults determined to be at high risk for mpox infection.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Emergent-Biosolutions-Inc-US29089Q1058/load_more?page=3">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>